Why self-reported data fails clinical trials — and how RWD and AI fix enrollment accuracy before the first patient is dosed.
Feature|Articles|September 24, 2026
What Actually Went Wrong When a Phase 3 Trial Fails: Q&A with Dr. Remo Moomiaie-Qajar
Author(s)Dr. Remo Moomiaie-Qajar
Drug-delivery failures — not flawed science — are the hidden driver of late-stage trial failures.
Advertisement
Advertisement
The long, complex process that it takes to successfully bring a drug to market is one of the biggest issues mentioned by members of the pharmaceutical and biotech industries. From a business standpoint, investors are wary to spend money on a molecule only for it to take years to discover that it’s not a viable treatment.
Related to this article
Inovalon's Jen Lamppa on why AI's ability to extract insights from unstructured clinical data is foundational to making RWD usable in trials.
Novartis has agreed to pay BoomRay up to $900 million for exclusive global rights to an undisclosed preclinical radioligand therapy asset.
Inovalon's Jen Lamppa on why FDA's acceptance of RWD downstream is a call to action for sponsors to start using it upstream in trial design.
AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.
Novo Nordisk reports that CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial, outperforming tirzepatide's 9.1% at comparable doses.
Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
Advertisement
Advertisement